Health Update

For indispensable reporting on the coronavirus crisis and more, subscribe to Mother Jones' newsletters.


As I mentioned a couple of weeks ago, my chemo regimen changed last month. The Revlimid reduced my M-protein level for a little while, but then flattened out around 0.6, which is still a long way from zero.1 So now we’re trying Revlimid plus dexamethasone. Dex is pure evil, but it’s also pretty good at fighting multiple myeloma, so let’s all give a big round of applause to evil! My first test result came back yesterday, and after only three weeks on the dex my M-protein marker has finally budged from 0.6. It’s now down to 0.48. There’s still a long way to go, but at least things are once again moving in the right direction.

1Standard explainer: myeloma cells produce M-proteins, so measuring them is a good proxy for the level of cancerous cells in my bone marrow. This will never get to zero, but when the M-protein marker reaches zero it means the myeloma is at a very, very low level. So that’s the goal.

Dear Reader,

This feels like the most important fundraising drive since I've been CEO of Mother Jones, with staggeringly high stakes and so much uncertainty. In "News Is Just Like Waste Management," I try to unpack the reality we all face and how we can rise to the challenge. If you're able to, this is a critical moment to support Mother Jones’ nonprofit journalism: We need to raise $400,000 to help cover the vital reporting projects we have planned, and right now is no time to pull back.

Monika Bauerlein, CEO, Mother Jones

Dear Reader,

This feels like the most important fundraising drive since I've been CEO of Mother Jones, with staggeringly high stakes and so much uncertainty. In "News Is Just Like Waste Management," I try to unpack the reality we all face and how we can rise to the challenge. If you're able to, this is a critical moment to support Mother Jones’ nonprofit journalism: We need to raise $400,000 to help cover the vital reporting projects we have planned, and right now is no time to pull back.

Monika Bauerlein, CEO, Mother Jones

We Recommend

Latest

Sign up for our newsletters

Subscribe and we'll send Mother Jones straight to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate

We have a new comment system! We are now using Coral, from Vox Media, for comments on all new articles. We'd love your feedback.